newsfilter
← Latest News
GlobeNewswire·

Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A EVERLAST-A responses continued to deepen to 71% PASI 100 at Week 28, 6 months after last